Sialidosis (Cherry Red Spot Myoclonus Syndrome) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Sialidosis is a rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme neuraminidase (also called sialidase), which is responsible for cleaving sialic acid residues from glycoproteins and glycolipids. The deficiency leads to accumulation of sialylated oligosaccharides in various tissues throughout the body, particularly in the brain, eyes, and peripheral nerves1.
The disease is characterized by the classic combination of a cherry-red spot at the macula of the eye, progressive myoclonus (involuntary muscle jerks), and ataxia (loss of coordination). Sialidosis is also known as cherry-red spot myoclonus syndrome2.
Sialidosis is classified into two main types based on age of onset and severity:
Type I sialidosis typically presents in the second or third decade of life (adolescence to young adulthood). It is the milder form and is characterized by:
- Visual disturbances due to cherry-red spot maculopathy
- Progressive myoclonus
- Ataxia
- Intact cognition in most cases
- Slowly progressive disease course
Type II sialidosis presents in infancy or early childhood and is more severe:
- Onset in first year of life
- Severe developmental delay
- Coarse facial features (dysostosis multiplex)
- Organomegaly (enlarged liver and spleen)
- Cherry-red spot
- Myoclonus and seizures
- More rapid progression
¶ Genetics and Molecular Basis
Sialidosis is caused by mutations in the NEU1 gene (neuraminidase 1), located on chromosome 6p21.3. This gene encodes the lysosomal neuraminidase enzyme, which is essential for catabolism of sialylated glycoconjugates3.
Sialidosis follows autosomal recessive inheritance. Both copies of the NEU1 gene must be mutated for the disease to manifest. Parents of an affected child are typically asymptomatic carriers, with a 25% risk of having an affected child in each subsequent pregnancy.
The primary biochemical defect is deficiency of lysosomal neuraminidase (EC 3.2.1.18), which normally catalyzes the removal of terminal sialic acid residues from glycoproteins and glycolipids. Without functional neuraminidase, sialylated compounds accumulate within lysosomes, particularly in:
- Neurons of the central nervous system
- Retinal ganglion cells
- Peripheral nerve cells
- Various visceral organs
The accumulation of sialylated compounds in neurons leads to:
- Neuronal dysfunction and death - particularly in the cerebellum, brainstem, and spinal cord
- Retinal degeneration - accumulation in retinal ganglion cells causes the characteristic cherry-red spot
- Synaptic dysfunction - disruption of normal neuronal communication
- Progressive neurodegeneration - accounting for the worsening myoclonus and ataxia over time
The precise mechanisms linking lysosomal storage to neuronal dysfunction remain an active area of research, but likely involve:
- Impaired autophagy
- Endoplasmic reticulum stress
- Oxidative stress
- Disrupted calcium homeostasis
- Cherry-red spot maculopathy - the hallmark finding, caused by accumulation of storage material in retinal ganglion cells at the macula, which appears bright red against the pale surrounding retina
- Progressive visual loss
- Night blindness (nyctalopia)
- Color vision defects
- Progressive myoclonus - involuntary, shock-like muscle jerks that worsen with movement
- Cerebellar ataxia - loss of coordination, gait instability, dysmetria
- Seizures - particularly in Type II
- Cognitive impairment - more common in Type II
- Peripheral neuropathy - in some cases
- Coarse facial features
- Hepatomegaly and splenomegaly
- Skeletal abnormalities
- Recurrent infections
The diagnosis is suspected based on:
- Clinical presentation (myoclonus, ataxia, cherry-red spot)
- Family history (autosomal recessive pattern)
- Age of onset
- Enzyme assay - measurement of neuraminidase activity in leukocytes or fibroblasts (reduced or absent activity confirms diagnosis)
- Urinary oligosaccharide analysis - detection of increased sialylated oligosaccharides
- Molecular genetic testing of NEU1 gene - identifies pathogenic variants
- Carrier testing for at-risk family members
- Prenatal diagnosis for families with known mutations
- MRI brain may show cerebellar atrophy in advanced cases
- Ophthalmologic examination including fundoscopy to visualize cherry-red spot
Currently, there is no cure for sialidosis. Treatment is supportive and focuses on symptom management:
- Anticonvulsants for myoclonus and seizures (e.g., valproic acid, clonazepam, levetiracetam)
- Physical therapy for ataxia and mobility
- Occupational therapy for daily living skills
- Vision rehabilitation for visual impairment
- Speech therapy if dysarthria develops
Research efforts are focused on:
- Enzyme replacement therapy - intravenous or intracerebroventricular delivery of recombinant neuraminidase
- Gene therapy - viral vector-mediated delivery of functional NEU1 gene
- Substrate reduction therapy - reducing the production of sialylated substrates
- Chaperone therapy - small molecules that help mutant enzymes fold correctly
- Bone marrow transplantation has been attempted in some cases
- Mesenchymal stem cell therapy is under investigation
- Various clinical trials are recruiting patients (clinicaltrials.gov)
Sialidosis is a rare disease with an estimated prevalence of 1 in 4,000,000 to 1 in 10,000,000 individuals. It affects males and females equally and has been reported in various ethnic groups worldwide. The higher incidence in certain populations may reflect founder effects.
Conditions to consider in the differential diagnosis include:
- Other lysosomal storage diseases (e.g., Galactosialidosis, Tay-Sachs disease, Sandhoff disease)
- Unverricht-Lundborg disease (progressive myoclonus epilepsy)
- Lafora disease
- Neuronal ceroid lipofuscinoses
- Friedreich ataxia
- Other causes of cherry-red spot (e.g., central retinal artery occlusion, toxic maculopathies)
The prognosis varies by type:
- Type I: Patients typically have a normal lifespan but experience progressive disability. Life expectancy may be normal or slightly reduced.
- Type II: More severe disease course with earlier onset. Prognosis is poorer, with many patients experiencing significant disability and reduced life expectancy.
Current research priorities include:
- Developing effective enzyme replacement or gene therapy approaches
- Understanding the natural history of the disease
- Identifying biomarkers for disease progression
- Clinical trials for emerging therapeutics
The study of Sialidosis (Cherry Red Spot Myoclonus Syndrome) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lowden JA, O'Brien JS. Sialidosis: a review of human neuraminidase deficiency. American Journal of Human Genetics. 1979;31(1):1-18.
- Spranger JW, Scholtz CL, Walka ME, et al. Sialidosis type I: cherry red spot myoclonus syndrome. Journal of Inherited Metabolic Disease. 1989;12(2):142-150.
- Bonten EJ, Arts WF, Beck M, et al. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity of sialidosis type I. American Journal of Human Genetics. 2000;66(6):1821-1831.
- Seyrantepe V, Hinek A, Peng J, et al. Enzymatic activity of human neuraminidase 1 (NEU1) variants: implications for sialidosis. Journal of Biological Chemistry. 2008;283(45):30481-30491.
- Pshezhetsky AV, Hinek A. Where do we stand on the development of therapy for sialidosis? The Canadian Journal of Neurological Sciences. 2011;38(3):395-401.
- Lukong KE, Hinek A, Sleat DE, et al. Mutations in the lysosomal neuraminidase-1 (NEU1) gene cause sialidosis. Human Mutation. 2000;15(1):99-103.
- Caciotti A, Melani F, Guerrini R, et al. Type I sialidosis, a normosomatic form with peripheral neuropathy. Neurology. 2003;60(6):1006-1008.
- Verheijen FW, Thoomes R, Galjaard RJ, et al. First case of type II sialidosis with severe neurological involvement and mosaicism for a deletion in the NEU1 gene. Annals of Neurology. 1999;45(2):265-269.